AK139 / Akesobio - LARVOL DELTA

Akeso, Inc…is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. (The Manila Times) - "These indications include chronic obstructive pulmonary disease (COPD), severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe atopic dermatitis, and prurigo nodularis."

New P2 trial • Allergic Rhinitis • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Immunology • Prurigo Nodularis

A Clinical Study of AK139 in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Akeso

New P1 trial

Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases (PRNewswire) - "Akeso...is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα and ST2. AK139 is under investigation for a number of indications, including respiratory and skin diseases....Preclinical studies have demonstrated that AK139 showcases strong dual-specific antigen-binding activity and promising pharmacological effects in both in-vitro and in-vivo. The antibody has shown remarkable synergy between the targets, significantly outperforming single-target antibodies targeting IL-4 or ST2 in key measures."

New trial • Preclinical • Dermatology • Respiratory Diseases